Abstract:Abstract Background SARS-CoV-2 infections usually cause immune dysregulation in the human body. Studies of immunological changes resulting from coinfections with Mycobacterium tuberculosis ( Mtb ) or HIV are limited. Methods We conducted a retrospective study focusing on patients with COVID-19. A total of 550 patients infected with SARS-CoV-2 were enrolled in our study and categorized into four groups based on the presence of coinfections; 166 Delta-infected patients, among whom 103 patients had no coinfections, 52 who were coinfected with Mtb , 11 who were coinfected with HIV, and 384 Omicron-infected patients. By collecting data on epidemiologic information, laboratory findings, treatments, and clinical outcomes, we analyzed and compared clinical and immunological characteristics. Results Compared with those in the Delta group, the median white blood cell, CD4 + T-cell and B-cell counts were lower in the Mtb group and the HIV group. Except for those in the Omicron group, more than half of the patients in the three groups had abnormal chest CT findings. Among the three groups, there were no significant differences in any of the cytokines. Compared with those in the Delta group, the disease duration and LOS were longer in the Mtb group and the HIV group. For unvaccinated Delta-infected patients, in the Mtb and HIV groups, the number of B cells and CD4 + T cells was lower than that in the Delta group, with no significant difference in the LOS or disease duration. In the Mtb group, three (6%) patients presented with a disease duration greater than four months and had decreased lymphocyte and IL17A counts, possibly due to double infections in the lungs caused by SARS-CoV-2 and M. tuberculosis. Conclusions We found that SARS-CoV-2 patients coinfected with Mtb or HIV exhibited a longer disease duration and longer LOS, with a decrease in B cells and CD4 + T cells, suggesting that these cells are related to immune function. Changes in cytokine levels suggest that coinfection with Mtb or HIV does not result in dysregulation of the immune response. Importantly, we discovered a chronic course of coinfection involving more than four months of Mtb and SARS-CoV-2 infection.

Long-term infection of SARS-CoV-2 changed the body's immune status

Clinical characteristics of pneumonia patients of long courses infected with SARS-CoV-2

Immune Characteristics of Patients with Coronavirus Disease 2019 (COVID-19)

Long-Term Existence of SARS-CoV-2 in COVID-19 Patients: Host Immunity, Viral Virulence, and Transmissibility

Clinical Characteristics and Factors Associated with Long-Term Viral Excretion in Patients with Severe Acute Respiratory Syndrome Coronavirus 2 Infection: a Single-Center 28-Day Study

Clinical characteristics of pneumonia patients of long course of illness infected with SARS-CoV-2

Dynamic Characteristic Analysis of Antibodies in Patients with COVID-19: A 13-Month Study

Investigation of the impact of SARS-CoV infection on the immunologic status and lung function after 15 years

Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients

Viral and Antibody Kinetics of COVID-19 Patients with Different Disease Severities in Acute and Convalescent Phases: A 6-Month Follow-Up Study

Neutralizing Antibodies and Cellular Immune Responses Against SARS-CoV-2 Sustained One and a Half Years After Natural Infection

Longitudinal Virological Changes and Underlying Pathogenesis in Hospitalized COVID-19 Patients in Guangzhou, China

The Dynamic Changes of Antibodies Against SARS-CoV-2 During the Infection and Recovery of COVID-19

Immune Responses in Discharged COVID-19 Patients With and Without Long COVID Symptoms

Data-Driven Analysis of COVID-19 Reveals Persistent Immune Abnormalities in Convalescent Severe Individuals

Immune Dysregulation in SARS-CoV-2 patients coinfected with Mycobacterium tuberculosis (Mtb) or HIV in China

Differential decline of SARS-CoV-2-specific antibody levels, innate and adaptive immune cells, and shift of Th1/inflammatory to Th2 serum cytokine levels long after first COVID-19

Viral and host factors related to the clinic outcome of the SARS CoV 2 infection

Immunological and Inflammatory Indicators of COVID-19 Patients With Returned-positive Nucleic Acid Tests During Hospitalization: a Retrospective Cohort Study

Dynamic Changes in Anti-Sars-cov-2 Antibodies During SARS-CoV-2 Infection and Recovery from COVID-19

Longitudinal Profiling of Antibody Response in Patients with COVID-19 in a Tertiary Care Hospital in Beijing, China